| |  Online-Ressource |
|---|
| Verfasst von: | Schreiber, Caroline [VerfasserIn]  |
|---|
| | Gruber, Annette [VerfasserIn] |
|---|
| | Roßwag, Sven [VerfasserIn] |
|---|
| | Saraswati, Supriya [VerfasserIn] |
|---|
| | Harkins, Shannon [VerfasserIn] |
|---|
| | Thiele, Wilko [VerfasserIn] |
|---|
| | Foroushani, Zahra Hajian [VerfasserIn] |
|---|
| | Munding, Natalie [VerfasserIn] |
|---|
| | Schmaus, Anja [VerfasserIn] |
|---|
| | Rothley, Melanie [VerfasserIn] |
|---|
| | Dimmler, Arno [VerfasserIn] |
|---|
| | Tanaka, Motomu [VerfasserIn] |
|---|
| | Garvalov, Boyan K. [VerfasserIn] |
|---|
| | Sleeman, Jonathan P. [VerfasserIn] |
|---|
| Titel: | Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis |
|---|
| Verf.angabe: | Caroline Schreiber, Annette Gruber, Sven Roßwag, Supriya Saraswati, Shannon Harkins, Wilko Thiele, Zahra Hajian Foroushani, Natalie Munding, Anja Schmaus, Melanie Rothley, Arno Dimmler, Motomu Tanaka, Boyan K. Garvalov, Jonathan P. Sleeman |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 1 May 2022 |
|---|
| Umfang: | 12 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online verfügbar: 15. Februar 2022, Artikelversion: 22. Februar 2022 ; Gesehen am 11.03.2024 |
|---|
| Titel Quelle: | Enthalten in: Cancer letters |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1975 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 533(2022) vom: Mai, Artikel-ID 215600, Seite 1-12 |
|---|
| ISSN Quelle: | 1872-7980 |
|---|
| Abstract: | ASAP1 is a multi-domain adaptor protein that regulates cytoskeletal dynamics, receptor recycling and intracellular vesicle trafficking. Its expression is associated with poor prognosis in a variety of cancers, and can promote cell migration, invasion and metastasis. Although amplification and expression of ASAP1 has been associated with poor survival in breast cancer, we found that in the autochthonous MMTV-PyMT model of luminal breast cancer, ablation of ASAP1 resulted in an earlier onset of tumor initiation and increased metastasis. This was due to tumor cell-intrinsic effects of ASAP1 deletion, as ASAP1 deficiency in tumor, but not in stromal cells was sufficient to replicate the enhanced tumorigenicity and metastasis observed in the ASAP1-null MMTV-PyMT mice. Loss of ASAP1 in MMTV-PyMT mice had no effect on proliferation, apoptosis, angiogenesis or immune cell infiltration, but enhanced mammary gland hyperplasia and tumor cell invasion, indicating that ASAP1 can accelerate tumor initiation and promote dissemination. Mechanistically, these effects were associated with a potent activation of AKT. Importantly, lower ASAP1 levels correlated with poor prognosis and enhanced AKT activation in human ER+/luminal breast tumors, validating our findings in the MMTV-PyMT mouse model for this subtype of breast cancer. Taken together, our findings reveal that ASAP1 can have distinct functions in different tumor types and demonstrate a tumor suppressive activity for ASAP1 in luminal breast cancer. |
|---|
| DOI: | doi:10.1016/j.canlet.2022.215600 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.canlet.2022.215600 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0304383522000751 |
|---|
| | DOI: https://doi.org/10.1016/j.canlet.2022.215600 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | AKT |
|---|
| | ASAP1 |
|---|
| | Hyperplasia |
|---|
| | Invasion |
|---|
| | Luminal breast cancer |
|---|
| | Metastasis |
|---|
| | MMTV-PyMT |
|---|
| K10plus-PPN: | 1883056764 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis / Schreiber, Caroline [VerfasserIn]; 1 May 2022 (Online-Ressource)
